Search the Newsreel

Colgate-Palmolive Readies Organization for Agentic Future

Colgate-Palmolive is undergoing a global digital transformation, heavily investing in AI, data, and analytics to create an "agentic future." CEO Noel Wallace detailed efforts to build an internal AI hub, develop data products, and redesign processes with embedded agents to enhance productivity and optimize …

Groupama Asset Managment Cuts Stock Holdings in Colgate-Palmolive Company $CL

Groupama Asset Management significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 90.5% in the first quarter, selling 23,585 shares and retaining 2,464. Despite this, institutional investors collectively own a substantial 80.41% of the company, and analysts maintain a "Moderate Buy" consensus rating with …

Edgestream Partners L.P. Has $1.70 Million Holdings in Colgate-Palmolive Company $CL

Edgestream Partners L.P. significantly increased its stake in Colgate-Palmolive Company (NYSE:CL) by 131% in the first quarter, now holding 19,924 shares valued at approximately $1.70 million. Institutional investors collectively own 80.41% of the company, which recently reported strong quarterly earnings of $0.99 EPS and …

Confluence Investment Management LLC Decreases Stock Holdings in Colgate-Palmolive Company $CL

Confluence Investment Management LLC reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 3.3% in the second quarter, now holding 1,209,372 shares worth $110.875 million, making it their 18th largest position. Despite this decrease, other institutional investors like Norges Bank and Bank of New York …

MOH|Molina Healthcare Inc|Price:194.740|Chg%:-0.880

This article provides a detailed financial and analytical overview of Molina Healthcare Inc (MOH), including its current

Colgate Palmolive (India) shares decline 2.07%

Colgate-Palmolive’s Q2 Earnings Beat on Nearly Every Line But Free Cash Flow Stole the Show.

JPMorgan Chase & Co. Lowers Colgate-Palmolive (NYSE:CL) Price Target to $103.00

JPMorgan Chase & Co. has reduced its price target for Colgate-Palmolive (NYSE:CL) from $104.00 to $103.00, while maintaining an "overweight" rating. This new price target suggests a potential upside of 12.76% from the company's previous closing price. Other analysts have also recently updated their …

RBC Capital raises Colgate-Palmolive stock price target on profit execution

RBC Capital increased its price target for Colgate-Palmolive (NYSE:CL) to $104 from $102, maintaining an Outperform rating due to strong profit execution despite mixed quarterly results. The company's gross profit margin of 60.43% was highlighted as a key strength, alongside an EPS beat driven …

TD Cowen raises Colgate-Palmolive stock price target on margin beat

TD Cowen has increased its price target for Colgate-Palmolive (NYSE:CL) stock to $90 from $

UBS Adjusts Price Target on Colgate-Palmolive to $109 From $106, Maintains Buy Rating

UBS has increased its price target for Colgate-Palmolive (CL) to $109 from $106, while maintaining a Buy rating on the stock. This adjustment comes amidst several other analyst revisions for Colgate-Palmolive on the same day, with most firms raising their price targets and maintaining …

Colgate Reports Strong Second Quarter 2026 Results

Colgate-Palmolive announced strong second-quarter 2026 financial results, with net sales increasing by 4.9% to $5.36 billion and adjusted earnings per share exceeding analyst expectations. The company saw regional growth in Latin America, Europe, the Middle East, Africa, and Asia-Pacific, while North America experienced a …

Colgate-Palmolive Company (CL) PT Raised to $90 at TD Cowen

TD Cowen analyst Robert Moskow has increased the price target for Colgate-Palmolive Company (NYSE: CL) to $90.00 from $85.00. This update indicates a positive outlook from the analyst for the consumer products giant. The article provides this key analyst action without further details, as …

RBC Capital Adjusts Colgate-Palmolive PT to $104 From $102, Maintains Outperform Rating

RBC Capital has increased its price target for Colgate-Palmolive (CL) to $104 from $102, while reiterating an Outperform rating on the stock. This adjustment comes amidst a series of analyst recommendations for Colgate-Palmolive, with several firms updating their price targets and ratings. The company …

Colgate-Palmolive Company $CL Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its stake in Colgate-Palmolive (NYSE:CL) by 5.7% in the first quarter, selling 148,594 shares but still retaining over 2.45 million shares valued at approximately $208.9 million. This comes as Colgate-Palmolive reported strong second-quarter adjusted EPS and revenue growth, though GAAP …

Jefferies raises Colgate-Palmolive stock price target on emerging markets strength

Jefferies has increased its price target for Colgate-Palmolive (NYSE:CL) to $89 from $88, citing strong performance in emerging markets. Despite a "Hold" rating, the firm acknowledges Colgate-Palmolive as a prime way to access emerging market growth within U.S. household and personal care equities. However, …

Molina Healthcare Inc (MOH) Stock Analysis: Navigating a 6.90% Potential Upside Amidst Mixed Performance Metrics

Molina Healthcare Inc (MOH) presents a complex investment case with a potential upside of 6.90% to an average target price of $209.12. Despite serving a critical demographic in healthcare, the company faces concerns due to a 5.70% decline in revenue and a slightly negative …

Morgan Stanley Adjusts PT on Colgate-Palmolive to $104 From $100, Maintain Overweight Rating

Morgan Stanley has increased its price target on Colgate-Palmolive (CL) to $104 from $100, while maintaining an "Overweight" rating on the stock. This adjustment comes after Colgate-Palmolive reported its Q2 2026 earnings, with the company also reaffirming its annual sales forecast and updating its …

Carmignac Gestion Cuts Stock Holdings in Colgate-Palmolive Company $CL

Carmignac Gestion significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 79.5% in the first quarter, selling over 900,000 shares. Despite this reduction by one institutional investor, other funds like Teacher Retirement System of Texas and Mirae Asset Global Investments Co. Ltd. increased their …

Colgate-Palmolive Company (CL) PT Raised to $89 at Jefferies

Jefferies analyst Kaumil Gajrawala increased the price target for Colgate-Palmolive Company (NYSE: CL) to $89.00 from $88.00. The analyst maintained a rating on the stock. This article is a premium-only content piece, requiring a subscription to StreetInsider.com Premium to view in full.

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported an 8% increase in Base Business EPS for Q2 2026, reaching $0.99, driven by gross margin expansion, organic sales growth, and improved operating profit. This occurred despite a 5% decline in reported EPS due to costs from its Strategic Growth and Productivity …

Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) securities who bought shares before February 5, 2025, and still hold them. The investigation aims to determine if Molina and its officers engaged in corporate wrongdoing. …

MOH5939489 Bond Profile — Key Metrics

This article provides a bond profile for Molina Healthcare, Inc. 6.25% 15-JAN-2033 (MOH5939489), detailing key metrics such as issue date, maturity date, outstanding amount, face value, and coupon rate. It identifies Molina Healthcare as a healthcare services provider with segments including Medicaid, Medicare, and …

First Nebraska Trust Co Takes $5.16 Million Position in Colgate-Palmolive Company $CL

First Nebraska Trust Co. has acquired a new stake worth approximately $5.16 million in Colgate-Palmolive Company, purchasing 60,532 shares. This comes as Colgate-Palmolive reported strong Q2 earnings, beating analyst estimates with $0.99 EPS and a 4.9% increase in revenue. Despite positive financial results and …

Colgate-Palmolive (CL) Stock Sees Revenue Strength Clash With Margin Strain

Colgate-Palmolive (CL) is experiencing revenue growth, particularly in premium oral care, pet nutrition, and emerging markets, with Q2 2026 net sales up mid-single digit. However, profitability remains a concern, with a trailing 12-month net margin of 10% compared to 14.5% the previous year, and …

Colgate-Palmolive Company $CL Stock Position Cut by Vestor Capital LLC

Vestor Capital LLC significantly cut its stake in Colgate-Palmolive (CL) by 95.1% in Q1 2026, selling over 30,000 shares but still retaining 1,560 shares. Despite this, other institutional investors increased their positions, and 80.41% of the stock is held by institutions. The article also …

Qué significan para los accionistas la reducción de los márgenes y las previsiones estables de Colgate-Palmolive (CL) para el segundo trimestre de 2026

Was der Margenrückgang im zweiten Quartal 2026 und die unveränderte Prognose von Colgate-Palmolive (CL) für die Aktionäre bedeuten

Colgate Palmolive (CL) Stock Trades At A Cash Flow Discount Despite An Earnings Premium

Colgate-Palmolive (CL) Earnings Keep Fair Value In Focus

What Colgate-Palmolive (CL)'s Q2 2026 Margin Squeeze And Steady Guidance Mean For Shareholders

Colgate-Palmolive reported increased sales in Q2 2026 but experienced a dip in net income and earnings per share due to margin squeeze from rising costs. Despite this, the company maintained its full-year 2026 guidance for 2% to 6% net sales growth and double-digit GAAP …

Colgate-Palmolive Co reports results for the quarter ended June 30 - Earnings Summary

Colgate-Palmolive Co (CL) has released its earnings summary for the quarter that concluded on June 30. The report, sourced from Refinitiv, is available for full viewing to subscribers of TradingView's news services.

Colgate-Palmolive hält an Gewinnprognose für das Gesamtjahr 2026 fest

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Colgate-Palmolive affirmed its annual

Colgate-Palmolive (CL) Q2 2026 Earnings

Colgate-Palmolive (CL) reported strong Q2 2026 earnings, beating EPS estimates by 4.5% with $0.99, extending its beat streak to five quarters. The company's revenue of $5.36 billion met expectations, and it saw accelerating volume growth despite a sales decline in North America. Following these …

Colgate-Palmolive (CL) Q2 Earnings and Revenues Top Estimates

Colgate-Palmolive (CL) reported strong Q2 earnings, beating Zacks Consensus Estimates with $0.99 per share and revenues of $5.36 billion. The company has consistently surpassed EPS estimates over the last four quarters and seen its shares gain 15.9% year-to-date, outperforming the S&P 500. While its …